Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Daniel Tassé | CEO & Director | 1.21M | -- | 1960 |
| Mr. Sébastien Robitaille | Chief Financial Officer | 335.17k | -- | 1970 |
| Dr. Pharis Mohideen | Chief Medical Officer | 725.12k | -- | 1965 |
| Mr. Pascal Wotling | Chief Technical Operations Officer & Chief Quality Officer | -- | -- | -- |
| Ms. Michele F. Robertson | Chief Legal Officer | -- | -- | -- |
| Ms. Caroline Daniere | Chief HR Officer & Chief of Staff | -- | -- | 1975 |
| Dr. Wence Agbotounou | Chief Clinical Trial Officer & Sr. VP | -- | -- | -- |
| Mr. Edward P. Jordan M.B.A. | Sr. VP of Commercial Operations North America | -- | -- | 1968 |
| Alan Kerr | Sr. VP & Head of Global Regulatory Affairs | -- | -- | -- |
DBV Technologies S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 88
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Corporate Governance
Upcoming Events
March 5, 2025 at 10:59 AM UTC - March 10, 2025 at 12:00 PM UTC
DBV Technologies S.A. Earnings Date
Recent Events
Recent Events Information Not Available